<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767869</url>
  </required_header>
  <id_info>
    <org_study_id>BANABA-MS</org_study_id>
    <nct_id>NCT02767869</nct_id>
  </id_info>
  <brief_title>Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity</brief_title>
  <official_title>Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult&#xD;
      population suffers the disease.&#xD;
&#xD;
      Banaba has shown evidence that has on metabolic syndrome, insulin sensitivity and insulin&#xD;
      secretion.&#xD;
&#xD;
      The investigators hypothesis was that the the administration of resveratrol modifies the&#xD;
      metabolic syndrome, insulin sensitivity and insulin secretion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients&#xD;
      with a diagnosis of metabolic syndrome in accordance with the International Diabetes&#xD;
      Federation (IDF). Waist circumference, glucose, insulin levels, and lipid profile were&#xD;
      evaluated after a 75 g of dextrose load.&#xD;
&#xD;
      12 received Banaba, 500 mg, two times per day (1000 mg) before meals during 3 months.&#xD;
&#xD;
      The remaining 12 patients received placebo with the same prescription.&#xD;
&#xD;
      Area Under the Curve of glucose and insulin was calculated as well as total insulin secretion&#xD;
      (insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin&#xD;
      sensitivity (Matsuda index).&#xD;
&#xD;
      This protocol was approved by a local ethics committee and written informed consent was&#xD;
      obtained from all volunteers.&#xD;
&#xD;
      Results are presented as mean and standard deviation. Intra and inter group differences were&#xD;
      tested using the Wilcoxon signed-rank and Mann-Whitney U-test respectively; p≤0.05 was&#xD;
      considered significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglyceride Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The triglycerides will be evaluated at week 12 with enzymatic-colorimetric techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Density Lipoprotein-cholesterol (HDL-C) Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The HDL-C levels will be evaluated at week 12 with enzymatic/colorimetric techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Glucose Levels at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The fasting glucose levels were evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic Blood Pressure at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The systolic blood pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the systolic blood pressure at week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First Phase of Insulin Secretion at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Insulin Secretion at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>Measure Description: The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Insulin Sensitivity at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Waist Circumference at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Waist circumference will be evaluated at baseline and at week 12 with a flexible tape</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Blood Pressure at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The diastolic blood pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the diastolic blood pressure at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The weight was measured at baseline and week 12 with a bioimpedance balance and the entered values reflect the weight at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The Body Mass index was calculated at baseline and at week 12 with the Quetelet index and the entered values reflect the body mass index at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The total cholesterol was estimated by standardized techniques at baseline and week 12 and the entered values reflect the total cholesterol level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density Lipoprotein-cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The LDL-C levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the c-LDL levels at week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Banaba</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Banaba capsules, 500mg, two times per day before meals during 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Banaba</intervention_name>
    <description>Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
    <arm_group_label>Banaba</arm_group_label>
    <other_name>Lagerstroemia speciosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients both sexes,&#xD;
&#xD;
          -  Age between 30 and 60 years,&#xD;
&#xD;
          -  Metabolic Syndrome according to the IDF criteria&#xD;
&#xD;
          -  Waist circumference&#xD;
&#xD;
          -  Man ≥90 cm&#xD;
&#xD;
          -  Woman ≥80 cm&#xD;
&#xD;
        And two of the following criteria:&#xD;
&#xD;
          -  High density lipoprotein&#xD;
&#xD;
          -  Man ≤40 mg/dL&#xD;
&#xD;
          -  Woman ≤50 mg/dL&#xD;
&#xD;
          -  Fasting glucose ≥100 mg/dL&#xD;
&#xD;
          -  Triglycerides ≥150 mg/dL&#xD;
&#xD;
          -  Blood pressure ≥130/85 mmHg&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed or suspected pregnancy&#xD;
&#xD;
          -  Women under lactation and/or puerperium&#xD;
&#xD;
          -  Hypersensibility to resveratrol&#xD;
&#xD;
          -  Physical impossibility for taking pills&#xD;
&#xD;
          -  Known uncontrolled renal, hepatic, heart or thyroid diseased&#xD;
&#xD;
          -  Previous treatment for the metabolic syndrome components&#xD;
&#xD;
          -  Body Mass Index ≥39.9 kg/m2&#xD;
&#xD;
          -  Fasting glucose ≥126 mg/dL&#xD;
&#xD;
          -  Triglycerides ≥500 mg/dL&#xD;
&#xD;
          -  Total cholesterol ≥240 mg/dL&#xD;
&#xD;
          -  Low density lipoprotein (c-LDL) ≥190 mg/dL&#xD;
&#xD;
          -  Blood Pressure ≥140/90 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45037</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <results_first_submitted>August 17, 2020</results_first_submitted>
  <results_first_submitted_qc>September 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <last_update_submitted>December 25, 2020</last_update_submitted>
  <last_update_submitted_qc>December 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel González Ortiz</investigator_full_name>
    <investigator_title>PHD</investigator_title>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>central obesity</keyword>
  <keyword>Banaba</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Banaba</title>
          <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Sample size was calculated in accordance of Jeyaseelan's clinical trial formula with a statistical confidence of 95%, statistical power of 80%, obtaining a total of 12 patients per group including 20% of expected loss.</population>
      <group_list>
        <group group_id="B1">
          <title>Banaba</title>
          <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="9.1"/>
                    <measurement group_id="B2" value="45.5" spread="6.5"/>
                    <measurement group_id="B3" value="45" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <description>Body weight was evaluated through a bioimpedance digital scale and results are reported in kg with a decimal.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" spread="11.6"/>
                    <measurement group_id="B2" value="78.8" spread="10.3"/>
                    <measurement group_id="B3" value="77.6" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="2.6"/>
                    <measurement group_id="B2" value="28.6" spread="3.8"/>
                    <measurement group_id="B3" value="28.6" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference</title>
          <description>Waist circumference was measured with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.0" spread="7.8"/>
                    <measurement group_id="B2" value="97.4" spread="8.8"/>
                    <measurement group_id="B3" value="97.2" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <description>Measure Description: Blood pressure was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of systolic blood pressure (SBP) and diastolic (DBP). The value was expressed on mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.5" spread="12.9"/>
                    <measurement group_id="B2" value="122.6" spread="9.6"/>
                    <measurement group_id="B3" value="122.0" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <description>Measure Description: Blood pressure was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of systolic blood pressure (SBP) and diastolic (DBP). The value was expressed on mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" spread="9.6"/>
                    <measurement group_id="B2" value="81.7" spread="5.5"/>
                    <measurement group_id="B3" value="79.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose 0'</title>
          <description>Measure Description: The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood samples were taken at the basal and at the minutes 0 and 120 after a 75 g oral dextrose load.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106.9" spread="7.9"/>
                    <measurement group_id="B2" value="106.7" spread="6.6"/>
                    <measurement group_id="B3" value="106.8" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose 120'</title>
          <description>Measure Description: The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood samples were taken at the basal and at the minutes 30, 60, 90 and 120 after a 75 g oral dextrose load.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131.3" spread="27.2"/>
                    <measurement group_id="B2" value="138.3" spread="28.2"/>
                    <measurement group_id="B3" value="134.8" spread="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cholesterol</title>
          <description>Measure Description: The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood was centrifuged at 2000 rpm and serum was separated into two aliquots to determine cholesterol</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217.5" spread="48.3"/>
                    <measurement group_id="B2" value="197.7" spread="37.3"/>
                    <measurement group_id="B3" value="207.6" spread="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>Measure Description: The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood was centrifuged at 2000 rpm and serum was separated into two aliquots: the first was immediately analyzed to determine triglycerides</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204.4" spread="38.9"/>
                    <measurement group_id="B2" value="200.8" spread="80.6"/>
                    <measurement group_id="B3" value="202.6" spread="59.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density lipoprotein-cholesterol (HDL-C)</title>
          <description>The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood was centrifuged at 2000 rpm and serum was separated into aliquots: the first was immediately analyzed to determine high-density lipoprotein-cholesterol (HDL-C)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="18.1"/>
                    <measurement group_id="B2" value="57.3" spread="20.4"/>
                    <measurement group_id="B3" value="59.0" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density lipoprotein-cholesterol (LDL-C)</title>
          <description>The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood was centrifuged at 2000 rpm and serum was separated into two aliquots: the first was immediately analyzed to determine low-density lipoprotein-cholesterol (LDL-C).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.1" spread="39.3"/>
                    <measurement group_id="B2" value="108.0" spread="35.3"/>
                    <measurement group_id="B3" value="108.0" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area under the curve (AUC) glucose</title>
          <description>The area under the curve (AUC) of glucose, (0.5 * glucose (G) 0´ + (G 30´+G 60´ + G 90´) + 0.5 * G 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperglycemia.</description>
          <units>mg*min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18567.6" spread="3480.6"/>
                    <measurement group_id="B2" value="19336.3" spread="3224.7"/>
                    <measurement group_id="B3" value="18951.9" spread="3352.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area under the curve (AUC) insulin</title>
          <description>The area under the curve (AUC) of insulin, (0.5 * Insulin (I) 0´ + (I 30´+I 60´ + I 90´) + 0.5 * I 120´) * 30; has been widely used for calculating the glycemic index and for evaluating the efficacy of medications for postprandial hyperinsulinemia.</description>
          <units>uU*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8445.9" spread="2384.8"/>
                    <measurement group_id="B2" value="7669.7" spread="2109.5"/>
                    <measurement group_id="B3" value="8057.8" spread="2247.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very low-density lipoprotein (VLDL)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="8.0"/>
                    <measurement group_id="B2" value="40.1" spread="7.7"/>
                    <measurement group_id="B3" value="40.5" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total insulin secretion</title>
          <description>The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at baseline.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.4" spread="0.2"/>
                    <measurement group_id="B2" value="0.4" spread="0.1"/>
                    <measurement group_id="B3" value="0.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>First phase of insulin secretion</title>
          <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at baseline.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="954.3" spread="285.3"/>
                    <measurement group_id="B2" value="910.3" spread="514.1"/>
                    <measurement group_id="B3" value="932.3" spread="399.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin sensitivity</title>
          <description>Matsuda Index value is used to indicate insulin resistance on diabetes.&#xD;
Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity at baseline</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="1.4"/>
                    <measurement group_id="B2" value="5.1" spread="2.7"/>
                    <measurement group_id="B3" value="5.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Triglyceride Levels at Week 12</title>
        <description>The triglycerides will be evaluated at week 12 with enzymatic-colorimetric techniques.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride Levels at Week 12</title>
          <description>The triglycerides will be evaluated at week 12 with enzymatic-colorimetric techniques.</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.0" spread="43.0"/>
                    <measurement group_id="O2" value="199.9" spread="101.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High Density Lipoprotein-cholesterol (HDL-C) Levels at Week 12</title>
        <description>The HDL-C levels will be evaluated at week 12 with enzymatic/colorimetric techniques.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein-cholesterol (HDL-C) Levels at Week 12</title>
          <description>The HDL-C levels will be evaluated at week 12 with enzymatic/colorimetric techniques.</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="11.2"/>
                    <measurement group_id="O2" value="58.4" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.530</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Glucose Levels at Week 12</title>
        <description>The fasting glucose levels were evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose Levels at Week 12</title>
          <description>The fasting glucose levels were evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.2" spread="7.4"/>
                    <measurement group_id="O2" value="104.2" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure at Week 12.</title>
        <description>The systolic blood pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the systolic blood pressure at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 12.</title>
          <description>The systolic blood pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the systolic blood pressure at week 12</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.3" spread="9.8"/>
                    <measurement group_id="O2" value="122.6" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>First Phase of Insulin Secretion at Week 12</title>
        <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>First Phase of Insulin Secretion at Week 12</title>
          <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at week 12.</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="913.9" spread="490.3"/>
                    <measurement group_id="O2" value="651.0" spread="405.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.799</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Insulin Secretion at Week 12.</title>
        <description>Measure Description: The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Total Insulin Secretion at Week 12.</title>
          <description>Measure Description: The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at week 12.</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.2"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Insulin Sensitivity at Week 12</title>
        <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity at week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Total Insulin Sensitivity at Week 12</title>
          <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity at week 12.</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="3.2"/>
                    <measurement group_id="O2" value="5.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.878</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Waist Circumference at Week 12</title>
        <description>Waist circumference will be evaluated at baseline and at week 12 with a flexible tape</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference at Week 12</title>
          <description>Waist circumference will be evaluated at baseline and at week 12 with a flexible tape</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" spread="7.9"/>
                    <measurement group_id="O2" value="97.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.919</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diastolic Blood Pressure at Week 12</title>
        <description>The diastolic blood pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the diastolic blood pressure at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 12</title>
          <description>The diastolic blood pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the diastolic blood pressure at week 12</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="9.2"/>
                    <measurement group_id="O2" value="76.5" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.254</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight at Week 12</title>
        <description>The weight was measured at baseline and week 12 with a bioimpedance balance and the entered values reflect the weight at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Weight at Week 12</title>
          <description>The weight was measured at baseline and week 12 with a bioimpedance balance and the entered values reflect the weight at week 12</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" spread="8.6"/>
                    <measurement group_id="O2" value="72.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.347</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index at Week 12</title>
        <description>The Body Mass index was calculated at baseline and at week 12 with the Quetelet index and the entered values reflect the body mass index at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index at Week 12</title>
          <description>The Body Mass index was calculated at baseline and at week 12 with the Quetelet index and the entered values reflect the body mass index at week 12</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="2.7"/>
                    <measurement group_id="O2" value="28.9" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol at Week 12</title>
        <description>The total cholesterol was estimated by standardized techniques at baseline and week 12 and the entered values reflect the total cholesterol level at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol at Week 12</title>
          <description>The total cholesterol was estimated by standardized techniques at baseline and week 12 and the entered values reflect the total cholesterol level at week 12</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.0" spread="39.6"/>
                    <measurement group_id="O2" value="201.7" spread="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.410</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low-density Lipoprotein-cholesterol (LDL-C) at Week 12</title>
        <description>The LDL-C levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the c-LDL levels at week 12</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Banaba</title>
            <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Low-density Lipoprotein-cholesterol (LDL-C) at Week 12</title>
          <description>The LDL-C levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the c-LDL levels at week 12</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="8.0"/>
                    <measurement group_id="O2" value="39.9" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the 12-week study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Banaba</title>
          <description>Banaba capsules, 500mg, two times per day before meals during 90 days&#xD;
Banaba: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Calcined magnesia capsules, 500mg, two times per day before meals during 90 days&#xD;
placebo: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>softening of stool</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>abdominal colic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>abdominal swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>pyrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Manuel González Ortiz</name_or_title>
      <organization>Institute of Experimental andl Clinical Therapeutics</organization>
      <phone>+52-33-10-58-52-00 ext 34212</phone>
      <email>uiec@prodigy.net.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

